

Title:  
Dermatology and Respiratory medications

Reference Number: RDF1362

Date of Response: 27/03/2023

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Northern & Eastern responses please

*Q1. How many patients were treated in February 2023 (or latest available month) by the Dermatology department with the following drugs:*

Drug	Eastern	Northern
<b>Abrocitinib (Cibinqo) -</b>	<5	0
<b>Baricitinib (Olumiant)</b>	<5	0
<b>Dupilumab (Dupixent)</b>	<5	0
<b>Omalizumab (Xolair)</b>	8	<5
<b>Tralokinumab (Adtralza)</b>	<5	0
<b>Upadacitinib (Rinvoq)</b>	<5	0

*Q2. How many patients were treated in February 2023 (or latest available month) by the Respiratory Medicine department with the following drugs:*

Drug	Eastern	Northern
<b>Benralizumab (Fasenra)</b>	56	<5
<b>Dupilumab (Dupixent)</b>	9	<5
<b>Omalizumab (Xolair)</b>	17	<5
<b>Reslizumab (Cinqaero)</b>	<5	0
<b>Mepolizumab (Nucala)</b>	14	0
<b>Tezepelumab (Tezspire)</b>	0	0

<5

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients/staff is less than or equal to five and could risk the identification of those patients/staff and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients/staff and should not be published.